Know Cancer

forgot password

Phase 1
18 Years
Not Enrolling

Thank you

Trial Information

OBJECTIVES: I. Determine the maximum tolerated dose (MTD) and dose limiting toxicity (DLT)
of LEM.

II. Measure the blood pharmacokinetics of LEM following IV administration.

III. Observe any anti-tumor effects of LEM.

PROTOCOL OUTLINE: This is an open-label study for patients with advanced and/or metastatic,
histologically-documented solid tumors considered to be unresponsive to available
conventional treatment.

LEM will be administered IV over 45 minutes. At least three patients will be studied at
each dose level and at least three patients will complete one 21-day course before any
patient is enrolled at the next dose level. Study drug administration will continue on an
every 3-week schedule in the absence of progressive disease or unacceptable toxicity. A
subsequent course of treatment may be administered at least 21 days after a prior LEM dose
has been administered when study criteria are met.

Cohorts of 3 patients per dose level will be studied. This will be expanded to 6 if a DLT
occurs, followed by a total of 6 patients at a possible MTD.

PROJECTED ACCRUAL: It is expected that 21 to 30 patients will be entered into the study to
determine the MTD: 3 per dose level, expanded to 6 if DLT occurs, followed by a total of 6
patients at a possible MTD. The dose level identified as the MTD may then be expanded up to
12 patients to permit additional safety assessment.

Inclusion Criteria

-Disease Characteristics-

Advanced (local and/or metastatic) histologically documented solid tumors

Disease is not considered responsive to available conventional modalities or treatments

-Prior/Concurrent Therapy-

Must be fully recovered from acute toxicities of any prior treatment with cytotoxic drugs,
radiotherapy or other anti-cancer modalities (returned to baseline before most recent

No radiotherapy, treatment with cytotoxic or biologic agents within 3 weeks prior to study
entry (6 weeks for mitomycin or nitrosoureas)

At least 2 weeks after any prior surgery or hormonal therapy

Chronic toxicities of grade 1 from prior treatment are permitted

-Patient Characteristics-

ECOG Performance status of 0-2

Must be at least 18 years of age

Must have the following clinical laboratory values: ANC at least 1,500/mm3; Platelets at
least 100,000/mm3; Hemoglobin at least 10 g/dL; albumin at least 3.0 mg/dL; Serum
creatinine at least 2.0 mg/dL; Total bilirubin not more than upper limit of normal; ALT,
AST, and alkaline phosphatase not more than 1.5 x upper limit of normal; LVEF by MUGA scan
greater than or equal to the lower limit of normal

Must sign informed consent

No pregnant and/or nursing patients. Women of child-bearing potential must have negative
serum or urine pregnancy test within 1 week prior to study entry. Sexually-active patients
(both men and women) must use acceptable contraceptive methods.

No active uncontrolled bleeding or bleeding diathesis (e.g., active peptic ulcer disease)

No active infection of any kind

No known HIV infection or viral hepatitis

No active heart disease including myocardial infarction within the previous 6 months,
symptomatic coronary artery disease, arrhythmias requiring medication, or congestive heart

No known CNS metastases

No patients receiving any other standard or investigational treatment for their cancer, or
any other investigational agent for any indication

No patients requiring immediate palliative treatment of any kind including surgery

No patients who have received a high-dose chemotherapy regimen with stem cell support in
the previous 6 months

No patients who have received a cumulative anthracycline dose greater than 250 mg/m2
(doxorubicin equivalent)

No patients unwilling or unable to follow protocol requirements

No patients with known hypersensitivity to mitoxantrone or liposomes.

Type of Study:


Study Design:

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Principal Investigator

Przemyslaw Twardowski, M.D.

Investigator Role:

Principal Investigator

Investigator Affiliation:

City of Hope National Medical Center


United States: Food and Drug Administration

Study ID:




Start Date:

August 2001

Completion Date:

June 2004

Related Keywords:

  • Tumors
  • Liposome Encapsulated Mitoxantrone (LEM)
  • solid tumors



H. Lee Moffitt Cancer Center and Research Institute Tampa, Florida  33612
Barbara Ann Karmanos Cancer Institute Detroit, Michigan  48201
City of Hope National Medical Center Los Angeles, California  91010
The Ohio State University Columbus, Ohio  43210